NEW YORK, March 22, 2017 /PRNewswire/ --
This morning, Stock-Callers.com features four equities in the Healthcaresector, and they are: Depomed Inc. (NASDAQ: DEPO), Novartis AG (NYSE: NVS), TherapeuticsMD Inc. (NYSE MKT: TXMD), and Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP). On March 16th, 2017, Charles
On Tuesday, shares in Newark, California headquartered Depomed Inc. saw a decline of 4.13%, ending the day at $15.10. The stock recorded a trading volume of 971,361 shares. The Company's shares are trading below their 50-day moving average by 11.86%. Moreover, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have a Relative Strength Index (RSI) of 36.49. DEPO complete research report is just a click away and free at:
Shares in Basel, Switzerland headquartered Novartis AG ended the day 1.70% lower at $74.39. A total volume of 3.74 million shares was traded, which was above their three months average volume of 3.35 million shares. In the previous three months and since the start of this year, the stock has gained 7.41% and 5.85%, respectively. The Company's shares are trading above their 50-day and 200-day moving averages by 2.57% and 0.59%, respectively. Furthermore, shares of Novartis, which researches, develops, manufactures, and markets a range of healthcare products worldwide, have an RSI of 52.01.
On March 09th, 2017, research firm Liberum initiated a 'Buy' rating on the Company's stock. The complimentary report on NVS can be downloaded at:
At the close of trading on Tuesday, shares in Boca Raton, Florida headquartered TherapeuticsMD Inc. finished 3.92% lower at $6.61 with a total trading volume of 1.69 million shares. The stock has advanced 17.83% in the last one month, 13.97% over the previous three months, and 14.56% on an YTD basis. The Company's shares are trading above their 50-day moving average by 8.96%. Additionally, shares of TherapeuticsMD, which operates as a women's health care product company, have an RSI of 55.64. Sign up for your complimentary research report on TXMD at:
New York-based Tonix Pharmaceuticals Holding Corp.'s shares recorded a trading volume of 95,087 shares at the end of yesterday's session. The stock closed the day 6.31% lower at $3.71. The Company's shares have skyrocketed 577.01% in the past month, 706.52% in the last three months, and 689.19% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 451.32% and 227.58%, respectively. Additionally, shares of Tonix Pharma, which develops medicines for common disorders of the central nervous system, have an RSI of 85.60. Get free access to your research report on TNXP at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Unintended pregnancies are very common these days, and so one in about four pregnant women go for ...
Dizziness is a feeling of being faint or unsteady whereas Vertigo is a feeling that you or your ...View All